Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program
To examine the impact of Australia's single dose infant varicella vaccination program, we assessed single dose varicella vaccine effectiveness (VE) in preventing hospitalised disease using two methods. Clinically confirmed varicella cases from the Paediatric Active Enhanced Disease Surveillance...
Gespeichert in:
Veröffentlicht in: | The Journal of infection 2019-03, Vol.78 (3), p.220-225 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 225 |
---|---|
container_issue | 3 |
container_start_page | 220 |
container_title | The Journal of infection |
container_volume | 78 |
creator | Quinn, Helen E. Gidding, Heather F. Marshall, Helen S. Booy, Robert Elliott, Elizabeth J. Richmond, Peter Crawford, Nigel McIntyre, Peter B. Macartney, Kristine K. |
description | To examine the impact of Australia's single dose infant varicella vaccination program, we assessed single dose varicella vaccine effectiveness (VE) in preventing hospitalised disease using two methods.
Clinically confirmed varicella cases from the Paediatric Active Enhanced Disease Surveillance (PAEDS) sentinel network were age-matched to 20 controls obtained from the Australian Immunisation Register. Conditional logistic regression models were used to estimate VE and compared with estimates obtained using our second approach.
There were 78 hospitalised varicella cases during the post vaccine introduction period from January 2008 to December 2015, who were eligible for funded varicella vaccination. Median age at onset was 4.5 years and more than half (59%) were vaccinated. The majority of children received one vaccine brand (Varilrix, GSK). The estimated case-control VE for one dose of vaccine against hospitalised varicella was 64.7% (95% CI: 43.3–78.0%); estimates using the screening method were not significantly different. Exclusion of children who were immunocompromised did not significantly alter VE estimates.
Although Australia's program has impacted on the burden of varicella disease, single dose VE against varicella hospitalisation is only moderate. Greater reductions in varicella disease could potentially be achieved by incorporation of a second vaccine dose into the program to minimise breakthrough disease and interrupt virus circulation. |
doi_str_mv | 10.1016/j.jinf.2018.11.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2155157605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016344531830358X</els_id><sourcerecordid>2155157605</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-2c6067c275fa62b6df02d712a9f96a692e1753426e18a8c9909200168eb6f7923</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gAfJ0cuumWyT3aCXIn6B4EW9hjQ7kZTupibbQv-9u2316GlgeOYd3oeQS2A5MJA3i3zhW5dzBlUOkDOmjsgYRMEzXk75MRn3UJFNp6IYkbOUFqwnCiVPyahggleVrMbEfproLS6Xhm6Mtb5Fis6h7fwGW0yJhg1GCoxu0cREfUtn69RFs_Tmljahxmg6pKsYuuEmtNTF0FDI6pB2669omnNy4swy4cVhTsjH48P7_XP2-vb0cj97zWwhZJdxK5ksLS-FM5LPZe0Yr0vgRjkljVQcoRTFlEuEylRWKaY46ytWOJeuVLyYkOt9bv_3e42p041Pu24thnXSHIQAUUomepTvURtDShGdXkXfmLjVwPQgVy_0IFcPcjWAHtRNyNUhfz1vsP47-bXZA3d7APuWG49RJ-uxtVj72OvRdfD_5f8A8byKWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2155157605</pqid></control><display><type>article</type><title>Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program</title><source>Elsevier ScienceDirect Journals</source><creator>Quinn, Helen E. ; Gidding, Heather F. ; Marshall, Helen S. ; Booy, Robert ; Elliott, Elizabeth J. ; Richmond, Peter ; Crawford, Nigel ; McIntyre, Peter B. ; Macartney, Kristine K.</creator><creatorcontrib>Quinn, Helen E. ; Gidding, Heather F. ; Marshall, Helen S. ; Booy, Robert ; Elliott, Elizabeth J. ; Richmond, Peter ; Crawford, Nigel ; McIntyre, Peter B. ; Macartney, Kristine K. ; PAEDS (Paediatric Active Enhanced Disease Surveillance) Network</creatorcontrib><description>To examine the impact of Australia's single dose infant varicella vaccination program, we assessed single dose varicella vaccine effectiveness (VE) in preventing hospitalised disease using two methods.
Clinically confirmed varicella cases from the Paediatric Active Enhanced Disease Surveillance (PAEDS) sentinel network were age-matched to 20 controls obtained from the Australian Immunisation Register. Conditional logistic regression models were used to estimate VE and compared with estimates obtained using our second approach.
There were 78 hospitalised varicella cases during the post vaccine introduction period from January 2008 to December 2015, who were eligible for funded varicella vaccination. Median age at onset was 4.5 years and more than half (59%) were vaccinated. The majority of children received one vaccine brand (Varilrix, GSK). The estimated case-control VE for one dose of vaccine against hospitalised varicella was 64.7% (95% CI: 43.3–78.0%); estimates using the screening method were not significantly different. Exclusion of children who were immunocompromised did not significantly alter VE estimates.
Although Australia's program has impacted on the burden of varicella disease, single dose VE against varicella hospitalisation is only moderate. Greater reductions in varicella disease could potentially be achieved by incorporation of a second vaccine dose into the program to minimise breakthrough disease and interrupt virus circulation.</description><identifier>ISSN: 0163-4453</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/j.jinf.2018.11.009</identifier><identifier>PMID: 30528868</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Chickenpox ; Effectiveness ; Immunisation ; Varicella zoster virus ; Varicella, Vaccine</subject><ispartof>The Journal of infection, 2019-03, Vol.78 (3), p.220-225</ispartof><rights>2018</rights><rights>Crown Copyright © 2018. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-2c6067c275fa62b6df02d712a9f96a692e1753426e18a8c9909200168eb6f7923</citedby><cites>FETCH-LOGICAL-c356t-2c6067c275fa62b6df02d712a9f96a692e1753426e18a8c9909200168eb6f7923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016344531830358X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30528868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quinn, Helen E.</creatorcontrib><creatorcontrib>Gidding, Heather F.</creatorcontrib><creatorcontrib>Marshall, Helen S.</creatorcontrib><creatorcontrib>Booy, Robert</creatorcontrib><creatorcontrib>Elliott, Elizabeth J.</creatorcontrib><creatorcontrib>Richmond, Peter</creatorcontrib><creatorcontrib>Crawford, Nigel</creatorcontrib><creatorcontrib>McIntyre, Peter B.</creatorcontrib><creatorcontrib>Macartney, Kristine K.</creatorcontrib><creatorcontrib>PAEDS (Paediatric Active Enhanced Disease Surveillance) Network</creatorcontrib><title>Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><description>To examine the impact of Australia's single dose infant varicella vaccination program, we assessed single dose varicella vaccine effectiveness (VE) in preventing hospitalised disease using two methods.
Clinically confirmed varicella cases from the Paediatric Active Enhanced Disease Surveillance (PAEDS) sentinel network were age-matched to 20 controls obtained from the Australian Immunisation Register. Conditional logistic regression models were used to estimate VE and compared with estimates obtained using our second approach.
There were 78 hospitalised varicella cases during the post vaccine introduction period from January 2008 to December 2015, who were eligible for funded varicella vaccination. Median age at onset was 4.5 years and more than half (59%) were vaccinated. The majority of children received one vaccine brand (Varilrix, GSK). The estimated case-control VE for one dose of vaccine against hospitalised varicella was 64.7% (95% CI: 43.3–78.0%); estimates using the screening method were not significantly different. Exclusion of children who were immunocompromised did not significantly alter VE estimates.
Although Australia's program has impacted on the burden of varicella disease, single dose VE against varicella hospitalisation is only moderate. Greater reductions in varicella disease could potentially be achieved by incorporation of a second vaccine dose into the program to minimise breakthrough disease and interrupt virus circulation.</description><subject>Chickenpox</subject><subject>Effectiveness</subject><subject>Immunisation</subject><subject>Varicella zoster virus</subject><subject>Varicella, Vaccine</subject><issn>0163-4453</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlb_gAfJ0cuumWyT3aCXIn6B4EW9hjQ7kZTupibbQv-9u2316GlgeOYd3oeQS2A5MJA3i3zhW5dzBlUOkDOmjsgYRMEzXk75MRn3UJFNp6IYkbOUFqwnCiVPyahggleVrMbEfproLS6Xhm6Mtb5Fis6h7fwGW0yJhg1GCoxu0cREfUtn69RFs_Tmljahxmg6pKsYuuEmtNTF0FDI6pB2669omnNy4swy4cVhTsjH48P7_XP2-vb0cj97zWwhZJdxK5ksLS-FM5LPZe0Yr0vgRjkljVQcoRTFlEuEylRWKaY46ytWOJeuVLyYkOt9bv_3e42p041Pu24thnXSHIQAUUomepTvURtDShGdXkXfmLjVwPQgVy_0IFcPcjWAHtRNyNUhfz1vsP47-bXZA3d7APuWG49RJ-uxtVj72OvRdfD_5f8A8byKWQ</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Quinn, Helen E.</creator><creator>Gidding, Heather F.</creator><creator>Marshall, Helen S.</creator><creator>Booy, Robert</creator><creator>Elliott, Elizabeth J.</creator><creator>Richmond, Peter</creator><creator>Crawford, Nigel</creator><creator>McIntyre, Peter B.</creator><creator>Macartney, Kristine K.</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201903</creationdate><title>Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program</title><author>Quinn, Helen E. ; Gidding, Heather F. ; Marshall, Helen S. ; Booy, Robert ; Elliott, Elizabeth J. ; Richmond, Peter ; Crawford, Nigel ; McIntyre, Peter B. ; Macartney, Kristine K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-2c6067c275fa62b6df02d712a9f96a692e1753426e18a8c9909200168eb6f7923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Chickenpox</topic><topic>Effectiveness</topic><topic>Immunisation</topic><topic>Varicella zoster virus</topic><topic>Varicella, Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quinn, Helen E.</creatorcontrib><creatorcontrib>Gidding, Heather F.</creatorcontrib><creatorcontrib>Marshall, Helen S.</creatorcontrib><creatorcontrib>Booy, Robert</creatorcontrib><creatorcontrib>Elliott, Elizabeth J.</creatorcontrib><creatorcontrib>Richmond, Peter</creatorcontrib><creatorcontrib>Crawford, Nigel</creatorcontrib><creatorcontrib>McIntyre, Peter B.</creatorcontrib><creatorcontrib>Macartney, Kristine K.</creatorcontrib><creatorcontrib>PAEDS (Paediatric Active Enhanced Disease Surveillance) Network</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quinn, Helen E.</au><au>Gidding, Heather F.</au><au>Marshall, Helen S.</au><au>Booy, Robert</au><au>Elliott, Elizabeth J.</au><au>Richmond, Peter</au><au>Crawford, Nigel</au><au>McIntyre, Peter B.</au><au>Macartney, Kristine K.</au><aucorp>PAEDS (Paediatric Active Enhanced Disease Surveillance) Network</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>2019-03</date><risdate>2019</risdate><volume>78</volume><issue>3</issue><spage>220</spage><epage>225</epage><pages>220-225</pages><issn>0163-4453</issn><eissn>1532-2742</eissn><abstract>To examine the impact of Australia's single dose infant varicella vaccination program, we assessed single dose varicella vaccine effectiveness (VE) in preventing hospitalised disease using two methods.
Clinically confirmed varicella cases from the Paediatric Active Enhanced Disease Surveillance (PAEDS) sentinel network were age-matched to 20 controls obtained from the Australian Immunisation Register. Conditional logistic regression models were used to estimate VE and compared with estimates obtained using our second approach.
There were 78 hospitalised varicella cases during the post vaccine introduction period from January 2008 to December 2015, who were eligible for funded varicella vaccination. Median age at onset was 4.5 years and more than half (59%) were vaccinated. The majority of children received one vaccine brand (Varilrix, GSK). The estimated case-control VE for one dose of vaccine against hospitalised varicella was 64.7% (95% CI: 43.3–78.0%); estimates using the screening method were not significantly different. Exclusion of children who were immunocompromised did not significantly alter VE estimates.
Although Australia's program has impacted on the burden of varicella disease, single dose VE against varicella hospitalisation is only moderate. Greater reductions in varicella disease could potentially be achieved by incorporation of a second vaccine dose into the program to minimise breakthrough disease and interrupt virus circulation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30528868</pmid><doi>10.1016/j.jinf.2018.11.009</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-4453 |
ispartof | The Journal of infection, 2019-03, Vol.78 (3), p.220-225 |
issn | 0163-4453 1532-2742 |
language | eng |
recordid | cdi_proquest_miscellaneous_2155157605 |
source | Elsevier ScienceDirect Journals |
subjects | Chickenpox Effectiveness Immunisation Varicella zoster virus Varicella, Vaccine |
title | Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Varicella%20vaccine%20effectiveness%20over%2010%20years%20in%20Australia;%20moderate%20protection%20from%201-dose%20program&rft.jtitle=The%20Journal%20of%20infection&rft.au=Quinn,%20Helen%20E.&rft.aucorp=PAEDS%20(Paediatric%20Active%20Enhanced%20Disease%20Surveillance)%20Network&rft.date=2019-03&rft.volume=78&rft.issue=3&rft.spage=220&rft.epage=225&rft.pages=220-225&rft.issn=0163-4453&rft.eissn=1532-2742&rft_id=info:doi/10.1016/j.jinf.2018.11.009&rft_dat=%3Cproquest_cross%3E2155157605%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2155157605&rft_id=info:pmid/30528868&rft_els_id=S016344531830358X&rfr_iscdi=true |